Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline

Quotient Sciences announced an AI-enhanced solution designed to identify promising drug formulations and accelerate early clinical decision-making for new treatments. The release positions the offering as a workflow and development-efficiency improvement for its contract research, development and manufacturing services, but provides no financial metrics, customer commitments, or quantified commercial impact.